TRANSTHYRETIN AMYLOIDOSIS – OVERVIEW OF TREATMENT METHODS
Abstract
ATTR amyloidosis is a rare disease associated with abnormal folding of the transthyretin (TTR) protein, leading to the deposition of amyloid fibrils in the heart and nervous system. Treatment to date has focused primarily on alleviating symptoms such as heart failure and neuropathy. Currently available disease-modifying therapies include TTR stabilizers (tafamidis, acoramidis), which prevent TTR tetramer dissociation, and gene silencers (siRNA and ASO), which reduce TTR production and slow the progression of polyneuropathy. Modern experimental strategies, including CRISPR-Cas9 gene editing and anti-ATTR monoclonal antibodies, offer the potential for one-time treatment and removal of existing amyloid deposits. The choice of therapy should be tailored to the patient's phenotype, disease stage, and clinical capabilities, and ongoing research will better determine the long-term efficacy and safety of new drugs.
The aim of this paper is to present contemporary therapeutic strategies in the treatment of transthyretin amyloidosis (ATTR), with particular emphasis on disease-modifying drugs such as TTR stabilizers, gene silencers, CRISPR-Cas9 gene editing therapies, and anti-ATTR monoclonal antibodies. The paper aims to evaluate the efficacy and safety of available therapies, discuss their clinical indications depending on the patient's phenotype (polyneuropathy, cardiomyopathy), and present directions for the development of new therapeutic strategies based on current clinical trials.
References
Bampatsias, D., Wardhere, A., & Maurer, M. S. (2024). Treatment of transthyretin cardiac amyloidosis. Current opinion in cardiology, 39(5), 407–416. https://doi.org/10.1097/HCO.0000000000001156
Dieu, D. C., Pernice, H. F., Muratovic, H., Wetzel, P. J., Barzen, G., Wieder, N. W., Werhahn, S. M., Heidecker, B., Spethmann, S., & Hahn, K. (2025). Real-world treatment management in hereditary transthyretin amyloidosis - an experience report and proposal for therapy switch decision criteria. Neurological research and practice, 7(1), 65. https://doi.org/10.1186/s42466-025-00428-6
Margolin, E., Stern, LK, Argiro, A., et al. Current and future treatment of transthyretin amyloid cardiomyopathy. Cardiol Ther 14 , 385–401 (2025). https://doi.org/10.1007/s40119-025-00424-6
Mallus MT, Rizzello V. Treatment of amyloidosis: present and future. Eur Heart J Suppl. 2023 Apr 21;25(Suppl B):B99-B103. doi: 10.1093/eurheartjsupp/suad082. PMID: 37091663; PMCID: PMC10120969
Nguyen, O., Kamna, D., & Masri, A. (2025). New therapies to treat cardiac amyloidosis. Current opinion in cardiology, 40(2), 98–106. https://doi.org/10.1097/HCO.0000000000001198
Shafi Rehman, Shameera Shaik Masthan, Ramzi Ibrahim, Hoang Nhat Pham, Danial Hassan, Fahad Ahmad, Mohammad Shahzad Asif, Ahmad Safdar, Zain Anwar, Shahzad Raza, Preethi William, Pharmacological Management of transthyretin amyloid cardiomyopathy: a scoping review, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 6, September 2024, Pages 547–556, https://doi.org/10.1093/ehjcvp/pvae044
Tschöpe C, Elsanhoury A, Kristen AV. Transthyretin amyloid cardiomyopathy—2025 update: current diagnostic approaches and new therapeutic options. Journal of Clinical Medicine . 2025; 14(13):4785. https://doi.org/10.3390/jcm14134785
Views:
29
Downloads:
13
Copyright (c) 2026 Hanna Pietruszewska , Michał Ziemba, Klaudia Zackiewicz, Agata Wińska, Oliwia Sędziak, Agata Ogórek, Michał Bzoma, Paweł Liszka, Katarzyna Kleszczewska, Izabela Majchrzak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
